Certain male baldness pattern associated with increased risk of aggressive prostate cancer
the ONA take:
According to a new study published online ahead of print in the Journal of Clinical Oncology, frontal plus moderate vertex baldness in men at age 45 is linked with an elevated risk for developing aggressive prostate cancer.
In the study, researchers analyzed data from 39,070 men who participated in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. In order to be included, patients had to have no prior cancer diagnoses, excluding nonmelanoma skin cancer, and be able to recall their hair-loss patterns at age 45 using a modified Norwood-Hamiton scale.
The researchers identified 1,138 cases of prostate cancer, 571 of which were aggressive, during a median follow-up of 2.78 years. Patients with frontal plus moderate vertex baldness at age 45 was not significantly linked with overall prostate cancer risk or nonaggressive prostate cancer risk compared with men with no baldness. By contrast, the same type of baldness was significantly associated with a 40% increased risk for developing aggressive prostate cancer. Other types of baldness were not associated with an increased risk of prostate cancer.
Baldness in men at age 45 is linked with an elevated risk for developing aggressive prostate cancer.
Increasingly, evidence is suggesting that both prostate cancer and male pattern baldness are linked to increased levels of androgens (male sex hormones) and androgen receptors.
In 2013, Medical News Today reported on a study from researchers at the University of Pennsylvania in Philadelphia, who found that African-American men who experience baldness were 69% more likely to develop prostate cancer than those with no baldness.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|